Filing Flows › 8-K events › Microbot Medical
Microbot Medical: regulation fd disclosure
Form 8-K filed Oct 27, 2026 · items 7.01
FDA decisionsMicrobot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System
What the filing says
Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System ELMNT IR also became the first account on the West Coast, marking a geographic expansion which aligns with the Company’s Full Market Release strategy.
Read the filing on SEC EDGAR →
Microbot Medical at a glance
Latest quarterQ2 2026
Revenue$241K
Operating marginn/m
IndustrySurgical & Medical Instruments & Apparatus
Microbot Medical, Q2 2026: revenue $241K. The chart follows the revenue to costs, profit and cash.
Microbot Medical: every quarter, Q/Q and Y/Y, holders and guidance →
Microbot Medical’s other material 8-Ks
- Nov 5, 2026 — FDA decisions Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Fu
- Oct 23, 2026 — FDA decisions Microbot Medical ® Attending Key Medical Conference to Engage with Decisionmakers as it Continues to
Other recent fda decisions
- Biovie Nov 6, 2026
- Acrivon Therapeutics Nov 6, 2026
- Entera Bio Nov 6, 2026
- Precision Biosciences Nov 5, 2026
- Sintx Technologies Nov 5, 2026
- Microbot Medical Nov 5, 2026
- Bioxytran Nov 5, 2026
- Palvella Therapeutics Nov 5, 2026
- ANI Pharmaceuticals Nov 5, 2026
- Teleflex Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.